You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
京新藥業(002020.SZ):2020年度淨利預增20%-30%
格隆匯 01-20 17:40

格隆匯1月20日丨京新藥業(002020.SZ)披露2020年度業績預吿,預計2020年度歸屬於上市公司股東的淨利潤6.24億元-6.77億元,同比增長20%-30%;扣除非經常性損益後的淨利潤4億元-4.63億元,同比變動-5%-10%;基本每股收益0.938元-1.016元。業績變動原因如下:

1、受藥品集採影響,公司相關製劑產品及原料藥產品價格有明顯下降;受新冠疫情影響,醫療器械國際ODM業務部分訂單推延或取消,報吿期公司整體銷售收入同比略有下降。

2、報吿期內,公司加強成本管控、精益生產管理、提質增效,管理效能進一步提升;隨着集採中標及實施推進,製劑產品結構進一步調整優化,部分核心產品銷售收入、盈利水平穩定增長中。

3、報吿期內,公司對外投資項目公允價值變動評估增值約1.1億元,影響非經常性損益同比增長約120%。公允價值變動評估增值為財務部門估算數據,公司已聘請專業機構進行評估測算,最終以第三方評估測算數據為準。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account